Life sciences and health care M&A update: Q1 2026

The clearest theme in Q1 2026 is the continued shift away from a hospital-centric delivery model toward more distributed care.

Life sciences and health care trends

  • Health care services
    Health care M&A activity showed minimal change in Q1 2026 with activity marginally higher than the 542 deals announced in Q4 2025.1
  • Health care technology
    Q1 2026 health care technology M&A activity moderated modestly, but total capital deployed increased sharply, which was driven by large-scale transactions.2
  • Life sciences and pharma services
    March represented a clear high-water mark, with $26.7 billion of announced deal value, approximately 85% of which was concentrated in the final 12 days of the month.3
  • Medical devices and supplies
    Trends are being driven by AI-enabled diagnostics and workflow automation, wider adoption of connected wearables and remote monitoring, and continued growth in minimally invasive and robotic procedures.4
  • Payors and payor services
    Cost containment remains a top priority for payers, driven by the projected rise in US health care spending to $7.7 trillion by 2032.5

 

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy, or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties, and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

References

1 Levin Associates, “Healthcare M&A deal volume stalls in Q1:26,” press release, April 15, 2026..
2 Heather Landi, “Digital health startups raked in $4B during Q1 with 12 megadeals driving investment,” Fierce Healthcare, April 8, 2026.
3 Katherine Powers, “Biopharma markets thaw: M&A and fundraising accelerate,Real Economy Blog, RSM US LLP, April 13, 2026.
4 44 International, “The medical device industry in 2026: Where innovation meets opportunity,” February 2, 2026.
HealthEdge, “Payer priorities 2026: Balancing cost, compliance, and connection in a time of disruption,” December 12, 2025.

Did you find this useful?

Thanks for your feedback